A Phase II Clinical Study to evaluate the efficacy and safety of NRC-AN-019 in cancer patients failing prior standard therapies
Latest Information Update: 30 Aug 2016
At a glance
- Drugs NRC AN 019 (Primary)
- Indications Advanced breast cancer; Chronic myeloid leukaemia; Gastrointestinal stromal tumours; Glioma; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Natco Pharma
- 04 Jul 2013 New trial record